Cancer Cell Research (Online ISSN: 2161-2609)

Cancer Cell Research 2022 9(33) 827-835; published online  02 April 2022

Abstract: Celecoxib is a new generation of non-steroidal anti-inflammatory drugs. It can inhibit the production of prostaglandins (PG) by selectively inhibiting cyclooxygenase-2 (COX-2), so as to achieve the effect of anti-inflammatory and analgesic. In this study, we used quantitative structure-activity relationship (QSAR) model to predict the IC50 values of those compounds and indicate their anti-inflammatory effect. The CODESSA program was utilized to calculate all the 63 compounds which came from four literatures, and established linear models as well. In the linear QSAR model, R²、R²cv、S² were selected for model evaluation, and their values in each group were calculated, respectively. Moreover, we divided all these compounds into training set and test set randomly, and established nonlinear model by the gene expression programming (GEP) method, R² and MSE were calculated respectively. As a result, in the training set, R² and MSE were 0.93,0.04 in Group 1, 0.91, 0.002 in Group 2, 0.73, 0.03 in Group 3, 0.85,0.004 in Group 4.In the test set, R² and MSE were 0.74, 1.12 in Group 1, 0.85, 0.14 in Group 2, 0.64, 0.02 in Group 3, 0.727, 0.01 in Group 4. Ultimately, we found that the consequence of nonlinear model is better than that of linear model in each group. Hence, nonlinear model was supposed the development of these compounds as COX-2 inhibitor.

Cancer Cell Research 2022 9(33) 836-840; published online  29 May 2022

Abstract: Cervical cancer is one of the most common malignancies in women. The combination of human papillomavirus (HPV) genotyping with thinprep liquid-based cytology test (TCT) of cervical exfoliated cells and HPV vaccine helps greatly for the early diagnosis and prevention of cervical cancer. However, there is still a certain risk of missed diagnosis or over-diagnosis due to the limitations of its methodology. Therefore, women infected with high-risk HPV (hrHPV) need more reliable tests to identify whether the lesions will progress to cancer, which can guide early and accurate treatment and prevent over-treatment. Recently, studies have found that FAM19A4/mir124-2 methylation is closely related to cervical cancer, and its methylation degree increases with the severity of cervical lesions, which is expected to become a new biomarker of cervical cancer. Here, we summarized the clinical application value of FAM19A4/mir124-2 methylation test in hrHPV-positive women.